Altamira Therapeutics Ltd.
CYTO · NASDAQ
12/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Revenue | – | – | – | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | – | – | – | $0 |
| Gross Profit | – | – | – | -$0 |
| % Margin | – | – | – | -101.2% |
| R&D Expenses | – | – | – | $1 |
| G&A Expenses | – | – | – | $1 |
| SG&A Expenses | – | – | – | $1 |
| Sales & Mktg Exp. | – | – | – | $0 |
| Other Operating Expenses | – | – | – | $0 |
| Operating Expenses | – | – | – | $2 |
| Operating Income | – | – | – | -$2 |
| % Margin | – | – | – | -4,348.2% |
| Other Income/Exp. Net | – | – | – | -$0 |
| Pre-Tax Income | – | – | – | -$3 |
| Tax Expense | – | – | – | $0 |
| Net Income | – | – | – | -$3 |
| % Margin | – | – | – | -5,140.8% |
| EPS | – | – | – | -12.91 |
| % Growth | – | – | – | – |
| EPS Diluted | – | – | – | -12.91 |
| Weighted Avg Shares Out | – | – | – | 0 |
| Weighted Avg Shares Out Dil | – | – | – | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | – | – | – | $0 |
| Interest Expense | – | – | – | $1 |
| Depreciation & Amortization | – | – | – | $2 |
| EBITDA | – | – | – | -$0 |
| % Margin | – | – | – | -781.3% |